SNPs and GVHD prediction: Where to next?

Blood

Volumn 119, Issue 22, 2012, Pages 5066-5068

  Dickinson, Anne M ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE DISEASE; COMPUTER PROGRAM; EFFECTOR CELL; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; NOTE; ORGAN DONOR; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84861819122     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-409078     Document Type: Note

References (13)

1. Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012;119(22):5311- 5319.
2. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood. 1998;92(10):3943-3948. (Pubitemid 28525221)
3. Karabon L, Wysoczanska B, Bogunia-Kubik K, Suchnicki K, Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol. 2005;66(6): 700-710. (Pubitemid 40922558)
4. Invernizzi P, Gershwin ME. The genetics of human autoimmune disease. J Autoimmun. 2009;33(3-4):290-299.
5. Vannucchi AM, Guidi S, Guglielmelli P, et al. Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40(10):1001-1002. (Pubitemid 350048202)
6. Snanoudj R, de Preneuf H, Creput C, et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int. 2006;19(9):693-704. (Pubitemid 44196157)
7. Landfried K, Zhu W, Waldhier MC, et al. Tryptophan catabolism is associated with acute GVHD after human allogeneic stem cell transplantation and indicates activation of indoleamine 2,3-dioxygenase. Blood. 2011;118(26):6971- 6974.
8. Vignali DAA, Collison LW, Workman CJ. How regulatoryTcells work. Nat Rev Immunol. 2008;8(7):523-532.
9. Hansen JA, Chien JW, Warren EH, Zhao LP, Martin PJ. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol. 2010;17(6):483-492.
10. Chien JW, Zhao LP, Storer B, et al. Improving hematopoietic cell transplant outcomes in a new era of genomic research. Biol Blood Marrow Transplant. 2009;15(1 Suppl): 42-45.
11. Pearce KF, Lee SJ, Haagenson M, et al. Analysis of non-HLA genomic risk factors in HLA-matched unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia [published online ahead of print January 25, 2012]. Haematologica. doi:10.3324/haematol.2011.053611.
12. Pociot F, Akolkar B, Concannon P, et al. Genetics of type 1 diabetes: what's next? Diabetes. 2010;59(7):1561-1571.
13. Gratwohl A, Stern M, Brand R, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer. 2009;115(20): 4715-4726.